CD19 and neoplasm: The motility of CD19‐CAR‐NK cell preparations was similar to that of non‐transduced NK cells in hyperplastic lymphoid tissue, with improved targeted migration in tumour tissue, suggesting the suitability of genetically engineered NK cells for difficult‐to‐reach tumour tissues.